NeoImmuneTech Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	94.82	170.38	-	-	-
Revenue Growth (YoY)	-44.35%	-	-	-	-
Gross Profit	94.82	170.38	-	-	-
Selling, General & Admin	22,817	36,534	52,369	55,326	50,090
Amortization of Goodwill & Intangibles	655.52	529.12	506.4	501.18	443.95
Operating Expenses	25,434	41,143	55,847	58,182	51,906
Operating Income	-25,339	-40,972	-55,847	-58,182	-51,906
Interest Expense	-2,424	-726.09	-225.28	-261.39	-219.15
Interest & Investment Income	1,255	1,788	2,877	1,154	390.88
Currency Exchange Gain (Loss)	-1,859	-1,335	-128.89	-3,005	-589.4
Other Non Operating Income (Expenses)	-3,614	1,187	23.06	18.52	15.46
EBT Excluding Unusual Items	-31,981	-40,059	-53,301	-60,276	-52,308
Gain (Loss) on Sale of Assets	213.95	-321.85	-1.91	-13.03	-104.72
Asset Writedown	-40.1	-488.92	-	-	-
Pretax Income	-31,807	-40,870	-53,303	-60,289	-52,413
Income Tax Expense	-11.37	12.83	101.3	116.41	69.47
Net Income	-31,796	-40,883	-53,405	-60,406	-52,482
Net Income to Common	-31,796	-40,883	-53,405	-60,406	-52,482
Shares Outstanding (Basic)	118	99	99	99	95
Shares Outstanding (Diluted)	118	99	99	99	95
Shares Change (YoY)	19.34%	-0.24%	0.08%	3.68%	15.27%
EPS (Basic)	-270.20	-414.60	-540.26	-611.60	-550.94
EPS (Diluted)	-270.20	-414.60	-540.40	-611.60	-550.94
Free Cash Flow	-25,133	-40,612	-50,552	-44,881	-36,596
Free Cash Flow Per Share	-213.57	-411.85	-511.40	-454.42	-384.18
Gross Margin	100.00%	100.00%	-	-	-
Operating Margin	-26721.84%	-24047.07%	-	-	-
Profit Margin	-33531.39%	-23994.58%	-	-	-
Free Cash Flow Margin	-26504.37%	-23835.33%	-	-	-
EBITDA	-22,841	-37,299	-52,637	-55,380	-50,033
D&A For EBITDA	2,498	3,673	3,210	2,802	1,873
EBIT	-25,339	-40,972	-55,847	-58,182	-51,906

Source: S&P Global Market Intelligence. Standard template. Financial Sources.